Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Teprotumumab Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentHealthSpringPolicy RX501.110

    Teprotumumab-trbw Coverage Criteria

    Customize your policy alerts

    Sign up for healthspring Policy RX501.110 alerts

    Get alerted when Policy RX501.110 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Provides coverage guidance for teprotumumab-trbw, subject to medical-necessity requirements, member benefits, contracts, and applicable state regulations.

    Policy Summary
    PayerHealthSpring
    PolicyTeprotumumab-trbw Coverage Criteria
    Policy CodePolicy RX501.110
    Change TypeNo material change
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument that the individual is at least 18 years old and has moderate-to-severe thyroid eye disease confirmed by at least one qualifying manifestation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Thyroid eye diseaseCovered indication
    18+Minimum age
    1 of 5Qualifying findings
    8 dosesInitial course
    J3241HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    General Medical-Necessity Requirements

    A requested drug therapy must meet all of the following medical-necessity requirements:

    ALL of the following

    • The requested therapy is proven effective for the relevant diagnosis or procedure.
    • The proposed dose, frequency, and duration of therapy are consistent with recommendations in at least one authoritative source.
    • The therapy is supported by FDA-approved labeling and/or nationally recognized authoritative references, including major drug compendia, peer-reviewed scientific literature, generally accepted standards of medical care, professional society guidelines, or CMS coverage policy.

    Ohio Off-Label Coverage Exception

    For Ohio members, coverage of an FDA-approved drug for an off-label use may be required when ALL of the following conditions are met:

    ALL of the following

    • The member resides in Ohio and the applicable group or individual policy covers prescription drugs.
    • The drug is approved by the U.S. Food and Drug Administration.
    • The requested use is recognized as safe and effective for treatment of the indication in one or more standard medical reference compendia adopted by the U.S. Department of Health and Human Services or in medical literature.
    • ONE of the following evidence pathways

      • The requested use is recognized as safe and effective in one or more adopted standard medical reference compendia.
      • Safety and efficacy for the proposed off-label use are confirmed in two articles from major peer-reviewed professional medical journals, such as the Journal of the American Medical Association, New England Journal of Medicine, or Lancet.

        Accepted study designs may include randomized, double-blind, placebo-controlled clinical trials. Case studies or case series alone are not sufficient.

    Initial Therapy for Thyroid Eye Disease

    Teprotumumab-trbw (Tepezza) may be considered medically necessary for thyroid eye disease when ALL of the following are met:

    ALL of the following

    • The individual is 18 years of age or older.
    • Moderate-to-severe thyroid eye disease is confirmed by at least ONE of the following

      • Lid retraction of 2 or more millimeters.>= 2 mm
      • Moderate-to-severe soft tissue involvement.
      • Exophthalmos of 3 millimeters or more.>= 3 mm

    Initial Therapy

    Initial therapy with teprotumumab-trbw is medically necessary only when ALL of the following apply:

    ALL of the following

    • The requested drug is teprotumumab-trbw (Tepezza).
    • The requested treatment is for thyroid eye disease meeting the eligibility criteria specified in this policy.
    • The requested course is the initial course of treatment, consisting of no more than 8 doses.

    For members residing in Ohio, carefully check state regulations and the member contract. Ohio Revised Code § 3923.60 requires applicable group or individual policies that cover prescription drugs to provide coverage for an FDA-approved drug when prescribed for a use recognized as safe and effective for the indication in an adopted standard medical reference compendium or qualifying medical literature, even when the FDA has not approved the drug for that indication. Coverage is never required when the FDA has recognized the use as contraindicated, and coverage is not required for non-formulary drugs.

    Teprotumumab-trbw (Tepezza) is considered experimental, investigational, and/or unproven for all other indications that are not approved by the U.S. Food and Drug Administration.

    Teprotumumab-trbw (Tepezza) is considered experimental, investigational, and/or unproven when used for a non-FDA-approved indication, except where an applicable coverage requirement—such as the Ohio off-label coverage exception—has been satisfied.

    Teprotumumab-trbw (Tepezza) is considered experimental, investigational, and/or unproven when used as a repeat course of treatment beyond the initial 8 doses.

    Coding and Coverage Parameters

    HCPCS CodesHCPCS
    J3241
    Lid Retraction
    Clinical findingLid retraction
    ThresholdAt least 2 millimeters
    Eligibility roleA qualifying manifestation of moderate-to-severe thyroid eye disease
    Exophthalmos
    Clinical findingExophthalmos
    ThresholdAt least 3 millimeters
    Eligibility roleA qualifying manifestation of moderate-to-severe thyroid eye disease

    Provider Documentation and Decision Points

    Documentation Required

    Document Clinical Eligibility

    Before requesting coverage, document that the individual is 18 years of age or older and has moderate-to-severe thyroid eye disease. Clinical confirmation must include at least one qualifying disease finding.

    • Lid retraction of 2 mm or more.
    • Moderate-to-severe soft tissue involvement.
    • Exophthalmos of 3 mm or more.
    • Presentation of diplopia.
    • Corneal exposure.
    Billing Rule

    Review Contraindicated or Non-Formulary Use

    Policy Background

    Coverage requires the requested drug therapy to be proven effective for the relevant diagnosis or procedure. The proposed dose, frequency, and duration must be consistent with recommendations in at least one authoritative source, such as FDA-approved labeling, a major drug compendium, peer-reviewed literature, professional society guidelines, or applicable CMS coverage policy. For teprotumumab-trbw, the labeled course is 8 intravenous infusions: an initial dose of 10 mg/kg, followed by 20 mg/kg for 7 additional infusions, administered every 3 weeks. Clinical studies reported week-24 proptosis responder rates of 71% and 83%, and a diplopia responder rate of 53%. Member benefits, contracts, and applicable state regulations govern when they differ from this medical policy; Ohio-specific requirements include the statutory off-label coverage exception described in this policy.

    Thyroid Eye Disease Definitions

    Mild Thyroid Eye Disease
    Lid retractionLess than 2 millimeters
    ExophthalmosLess than 3 millimeters
    Soft-tissue involvementMild
    Corneal exposureResponsive to topical lubrication
    Moderate-to-Severe Thyroid Eye Disease
    Lid retractionAt least 2 millimeters
    ExophthalmosAt least 3 millimeters

    Initial Tepezza Therapy

    Initial Tepezza Treatment

    Teprotumumab-trbw may be considered medically necessary for thyroid eye disease when all of the following criteria are met:

    Initial Tepezza treatment eligibility

    • Adult age: The individual is 18 years of age or older.≥ 18 years
    • Moderate-to-severe disease manifestation

      • Lid retraction of 2 or more millimeters.≥ 2 millimeters
      • Soft tissue involvement: Moderate to severe soft tissue involvement.

    Dose, Frequency, and Treatment Limits

    Tepezza Quantity Limit
    Initial courseInitial 8 doses
    Repeat coursesBeyond the initial 8 doses, repeat courses are experimental, investigational, and/or unproven
    Covered indicationThyroid eye disease
    Tepezza Dosing
    First infusion10 mg/kg intravenously
    Subsequent infusions20 mg/kg for 7 additional infusions
    Administration scheduleThe 7 additional infusions are administered every 3 weeks
    Policy Summary
    PayerHealthSpring
    PolicyTeprotumumab-trbw Coverage Criteria
    Policy CodePolicy RX501.110
    Change TypeNo material change
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument that the individual is at least 18 years old and has moderate-to-severe thyroid eye disease confirmed by at least one qualifying manifestation.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Documentation and Decision PointsPolicy BackgroundThyroid Eye Disease DefinitionsInitial Tepezza TherapyDose, Frequency, and Treatment Limits
    Presentation of diplopia.
  1. Corneal exposure.
  2. Minimum Age
    Minimum age18 years or older
    PopulationAdults
    Coverage requirementThe individual must meet the minimum age requirement for covered treatment
    Lid Retraction
    Clinical findingLid retraction
    ThresholdAt least 2 millimeters
    Qualifying statusOne of the findings that can confirm moderate-to-severe thyroid eye disease
    Exophthalmos
    Clinical findingExophthalmos
    ThresholdAt least 3 millimeters
    Qualifying statusOne of the findings that can confirm moderate-to-severe thyroid eye disease
    Repeat-Course Limit
    Treatment courseInitial course of teprotumumab-trbw treatment
    Covered limitInitial 8 doses
    Repeat coursesTreatment beyond the initial 8 doses is considered experimental, investigational, and/or unproven and is not covered

    Carefully check applicable state regulations and the member contract. For Ohio members, statutory coverage requirements may apply to FDA-approved drugs prescribed for recognized off-label uses, but coverage is not required when the FDA has recognized the use as contraindicated or for non-formulary drugs.

    • Ohio law may require coverage for an off-label use supported by an adopted standard medical compendium or by two articles from major peer-reviewed medical journals confirming safety and efficacy.
    • Case studies or case series alone do not satisfy the medical-literature standard.
    • The Ohio exception does not require coverage for FDA-recognized contraindicated uses or non-formulary drugs.
    Denial Risk

    Coverage Denial Triggers

    Coverage may be denied when the clinical record does not establish the required age, moderate-to-severe disease, or qualifying clinical confirmation for thyroid eye disease. Verify each requirement before submitting the request.

    • Confirm the individual is 18 years of age or older.
    • Confirm moderate-to-severe disease with at least one specified finding.
    • Ensure the supporting documentation clearly identifies the qualifying finding.
    Denial Risk

    Noncovered Indications or Repeat Treatment

    Tepezza is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications and when used for a repeat course beyond the initial 8 doses.

    • Do not submit repeat treatment beyond the initial 8 doses as a covered course.
    • Non-FDA-approved indications are noncovered under this policy.
    Denial Risk

    Age or Disease-Severity Criteria Not Met

    Deny or do not approve coverage when the individual is younger than 18 years or when moderate-to-severe thyroid eye disease is not confirmed by at least one required clinical finding.

    • Age requirement not met: individual is under 18.
    • Disease-severity requirement not met: no qualifying finding is documented.
    • Clinical confirmation is insufficient when the record lacks lid retraction, moderate-to-severe soft tissue involvement, qualifying exophthalmos, diplopia, or corneal exposure.
    Soft-tissue involvement
    Moderate to severe
    DiplopiaPresent
    Sight-Threatening Thyroid Eye Disease
    ConditionSight-threatening thyroid eye disease
    Optic nerve findingDysthyroid optic neuropathy
    Corneal findingCorneal breakdown
    Qualifying Findings
    Confirmation requirementAt least 1 qualifying clinical finding is required
    Finding 1Lid retraction of 2 or more millimeters
    Finding 2Moderate to severe soft-tissue involvement
    Finding 3Exophthalmos of 3 millimeters or more
    Finding 4Diplopia
    Finding 5Corneal exposure
    Moderate to severe
  3. Exophthalmos of 3 millimeters or more.≥ 3 millimeters
  4. Diplopia: Presentation of diplopia.Present
  5. Corneal exposure.Present
  6. Initial Treatment — Teprotumumab-trbw

    Teprotumumab-trbw may be considered medically necessary for the initial treatment of thyroid eye disease when all eligibility criteria are met:

    Initial treatment eligibility: The individual is 18 years of age or older and has moderate-to-severe thyroid eye disease confirmed by at least one qualifying finding: lid retraction of 2 or more millimeters, moderate to severe soft tissue involvement, exophthalmos of 3 millimeters or more, diplopia, or corneal exposure.Age ≥ 18 years and at least 1 qualifying finding
    Initial Treatment Limit
    Treatment typeInitial treatment
    Dose limit8 doses
    Course basisThe initial course of teprotumumab-trbw treatment